Abstract
Treating Alzheimers disease (AD) is one of todays biggest unmet medical needs. The drugs currently available transiently relieve some symptoms but have no significant effects on the progression of the disease. Progress in the past decade suggests that the amyloidogenesis of the inactive monomeric amyloid β peptide (Aβ) into a subset of toxic Aβ polymers is responsible for neurodegeneration in AD. Not all forms of Aβ aggregates are damaging, for there are patients whose brains accumulated large amounts of Aβ in the form of plaques, but they had no obvious neurodegeneration and symptoms of dementia. Since Aβ can polymerize into many types of polymers or aggregates, the form of Aβ that induces neurodegeneration in AD, defined here as bioactive Aβ, is not clear. Preventing the formation of bioactive Aβ or inactivating previously formed bioactive Aβ is a promising approach for treating AD. This review describes our efforts to develop a cell-based assay for detecting bioactive Aβ, to verify the concept of bioactive Aβ in an animal model of AD and in post mortem brain tissue from AD patients, and to use this assay to screen for drugs that can inactivate bioactive Aβ. These studies show the proof in principle that inactivating bioactive Aβ is a promising approach to treat AD. Several promising compounds that can inactivate bioactive Aβ species are also described.
Keywords: Alzheimer's disease, amyloid β peptide, amyloidogenesis, bioactive amyloid species, MTT, drug screening
Current Alzheimer Research
Title: Treating Alzheimers Disease by Inactivating Bioactive Amyloid β Peptide
Volume: 3 Issue: 2
Author(s): Yuanbin Liu and David Schubert
Affiliation:
Keywords: Alzheimer's disease, amyloid β peptide, amyloidogenesis, bioactive amyloid species, MTT, drug screening
Abstract: Treating Alzheimers disease (AD) is one of todays biggest unmet medical needs. The drugs currently available transiently relieve some symptoms but have no significant effects on the progression of the disease. Progress in the past decade suggests that the amyloidogenesis of the inactive monomeric amyloid β peptide (Aβ) into a subset of toxic Aβ polymers is responsible for neurodegeneration in AD. Not all forms of Aβ aggregates are damaging, for there are patients whose brains accumulated large amounts of Aβ in the form of plaques, but they had no obvious neurodegeneration and symptoms of dementia. Since Aβ can polymerize into many types of polymers or aggregates, the form of Aβ that induces neurodegeneration in AD, defined here as bioactive Aβ, is not clear. Preventing the formation of bioactive Aβ or inactivating previously formed bioactive Aβ is a promising approach for treating AD. This review describes our efforts to develop a cell-based assay for detecting bioactive Aβ, to verify the concept of bioactive Aβ in an animal model of AD and in post mortem brain tissue from AD patients, and to use this assay to screen for drugs that can inactivate bioactive Aβ. These studies show the proof in principle that inactivating bioactive Aβ is a promising approach to treat AD. Several promising compounds that can inactivate bioactive Aβ species are also described.
Export Options
About this article
Cite this article as:
Liu Yuanbin and Schubert David, Treating Alzheimers Disease by Inactivating Bioactive Amyloid β Peptide, Current Alzheimer Research 2006; 3 (2) . https://dx.doi.org/10.2174/156720506776383077
DOI https://dx.doi.org/10.2174/156720506776383077 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Involvement of Rat Hippocampal Astrocytes in β-Amyloid-Induced Angiogenesis and Neuroinflammation
Current Alzheimer Research Oxidative Stress Biology and Cell Injury During Type 1 and Type 2 Diabetes Mellitus
Current Neurovascular Research Sleep-Wake Patterns and Cognition of Older Adults with Amnestic Mild Cognitive Impairment (aMCI): A Comparison with Cognitively Healthy Adults and Moderate Alzheimer’s Disease Patients
Current Alzheimer Research Galanthum nivalis Extract is Neurologically Active and Improves Anxiety and Social Interactions in Mesocricetus auratus
The Natural Products Journal Central Selective Acetylcholinesterase Inhibitor with Neurotrophic Activity Structure-Activity Relationships of TAK-147 and Related Compounds
Current Medicinal Chemistry The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets Functional Connectivity in Elderly Controls and AD Patients Using Resting State fMRI: A Pilot Study
Current Alzheimer Research The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease
Current Medicinal Chemistry Hallucinations Associated with Topiramate Therapy: A Case Report and Review of the Literature
Current Drug Safety Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene]
Recent Patents on Drug Delivery & Formulation Neuroproteomics: Are We Biased in Our Representation of Molecular Targets Associated with Specific Domains? Implications in Biomarker Discovery
Current Proteomics Alpha7 Neuronal Nicotinic Receptor: A Pluripotent Target for Diseases of the Central Nervous System
CNS & Neurological Disorders - Drug Targets Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Multitarget Drugs of Plants Origin Acting on Alzheimer's Disease
Current Medicinal Chemistry Evidence of Redox Unbalance in Post-Acute Ischemic Stroke Patients
Current Neurovascular Research Drug-Related Decrease in Neuropsychological Functions of Abstinent Drug Users
Current Drug Abuse Reviews The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer’s Disease
Current Pharmaceutical Design Diabetes of the Brain: Computational Approaches and Interventional Strategies
CNS & Neurological Disorders - Drug Targets Hypertension, Cognitive Impairment and Dementia: An Epidemiological Perspective
Current Hypertension Reviews